MedTrace Logo

Circulating DNA in Surgically Treated NSCLC

NCT04037150 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-08-06

No results posted yet for this study

Summary

* The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up visits.
* This study aims to investigate the role of ctDNA in NSCLC patients treated with curative intent surgery.
* Preoperative ctDNA will be compared to primary tumor DNA to investigate the concordance of mutations and gained mutations from possible primary tumor cancer stem cell.
* Preoperative ctDNA findings will be tested for associations with baseline characteristics as well as clinically important factors such as TNM stage, histopathological findings, and tumor volume.
* The investigators aim to identify molecular residual disease (MRD) using multiple ctDNA samples after the surgery and search the associations with clinical recurrence and survival, with possible correlation to palliative chemotherapy response
* Using multiple ctDNA samples, the investigators will gather information about tumor heterogeneity, diversity of disease genotypes, and dynamic changes in ctDNA.
* If additional data from palliative immunotherapy (PD-L1 inhibitors) is available, the effect of this will be evaluated in the study.

Conditions

Interventions

DIAGNOSTIC_TEST

Circulating tumor DNA

Circulating tumor DNA

Sponsors & Collaborators

  • Institute for Molecular Medicine

    collaborator OTHER

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Ilkka Ilonen, PhD · Helsinki University Central Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04037150 on ClinicalTrials.gov